mynth
04/2016MajorityLBO

Eurazeo & Merieux Equity Partners take majority stake in Novacap

FRANCE Chemicals & Materials / Specialty Chemicals EV €500M–1.5bn

Context

Eurazeo and Mérieux Développement have signed an agreement to acquire a majority stake in Novacap from Ardian, which had held the company since March 2011. Ardian will retain a minority stake to maintain its commitment to the management team led by Pierre Luzeau. During Ardian's five-year ownership, Novacap underwent a massive transformation, executing six external acquisitions (notably in China and Germany) totaling approximately €240 million. This was complemented by an €85 million organic investment program to upgrade production tools. The strategic rationale for the new owners is to capitalize on Novacap’s reinforced position in high-margin target markets (pharmacy, health, and cosmetics), which now represent 68% of the group's activity compared to 44% previously. The transaction highlights Novacap's shift into a truly global player, with a strong footprint in Asia and a diversified revenue stream across essential chemical sectors. The new partnership aims to leverage Eurazeo’s financial strength and Mérieux’s healthcare network to pursue further international growth and solidify the group’s leadership in the specialty ingredients market.

In the past, Novacap was acquired by Ardian in 2010 as part of its expansion strategy.

Novacap, which reported an EBITDA margin of [members only] in 2015, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Industry & Manufacturing market trends

Target

Novacap is an international specialty chemicals group headquartered in Lyon, France, specializing in the production and distribution of essential chemical ingredients. The organization is a global leader across diversified end-markets, including pharmaceuticals, healthcare, cosmetics, fragrances, food, animal nutrition, and environmental services. Its extensive product portfolio includes active pharmaceutical ingredients (APIs) such as aspirin and paracetamol, as well as salicylic acid, soda ash, sodium bicarbonate, and oxygenated solvents. The business model transitioned from a France-centric operation to a global platform with 14 production facilities worldwide and a workforce of 1,600 people, half of whom are based in Asia. Organized into three divisions—Mineral Specialties, Pharmaceutical & Cosmetics, and Performance Chemicals—the group serves over 750 clients globally, emphasizing sustainable development and high-value chemical synthesis for mission-critical consumer products.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2015
€450–900M
€50–100M
[members only]
2014
€450–900M
€50–100M
[members only]

Other operations with Novacap

Other operations with Novacap
DateAcquirerTargetCountrySector
11/2010ARDIANNOVACAPFRANCESpecialty Chemicals

Other operations with Eurazeo / Merieux Equity Partners

Other operations with Eurazeo / Merieux Equity Partners
DateAcquirerTargetCountrySector
04/2019EURAZEOD.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)NETHERLANDSMedical Devices
05/2017EURAZEOGROUPE CPK (CARAMBAR POULAIN KREMA)FRANCEFood Products
03/2016EURAZEOGLION INSTITUTE / LES ROCHESSWITZERLANDEducation Providers
11/2015EURAZEOPLANET PAYMENTIRELANDFintech & Payments
09/2014EURAZEOCOLISÉEFRANCENursing Homes
03/2014EURAZEODESIGUALSPAINFashion & Apparel
02/2014EURAZEOVIGNAL GROUPFRANCEAuto Parts & Systems
01/2014EURAZEOASMODEE GROUPFRANCEConsumer Products
07/2013EURAZEOEVERNEXFRANCEMSP (Managed Services)
06/2013EURAZEOIES SYNERGYFRANCEBatteries & EV Tech

Similar deals in Chemicals & Materials

Similar deals in Chemicals & Materials
DateAcquirerTargetCountrySector
10/2016MANALI PETROCHEMICALSNOTEDOMEUNITED KINGDOMPlastics
07/2016IDEX CORPORATIONFTL SEALS TECHNOLOGYUNITED KINGDOMPlastics
03/2016SILVERFLEETCOVENTYAFRANCESpecialty Chemicals
01/2016ALLIANCE ETIQUETTESIMPRIMERIE MAUMYFRANCELabels & Adhesives
12/2015ALLIANCE ETIQUETTESNS ETIQUETTESFRANCELabels & Adhesives
10/2015APOLLO GLOBAL MANAGEMENT / BPIFRANCEVERALLIAFRANCEGlass Packaging
09/2015SCHWEITZER-MAUDUIT INTERNATIONAL (SWM)ARGOTECUNITED STATESPlastics
08/2015UNIQUE FABRICATINGGREAT LAKES FOAM TECHNOLOGIESUNITED STATESPlastics
07/2015ACTIVA CAPITALIMPRIMERIE LAULANFRANCELabels & Adhesives
06/2015INTERNATIONAL FLAVORS & FRAGRANCES (IFF)LUCAS MEYER COSMETICSCANADAFlavors & Fragrances

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €450–900M

EBITDA range: €50–100M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Novacap by Eurazeo / Merieux Equity Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Novacap, a French company specialised in Specialty Chemicals, by Eurazeo and Merieux Equity Partners in 2016, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in November 2010, when the company was acquired by Ardian.

How was the acquisition of Novacap by Eurazeo valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Novacap’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Novacap generated annual revenue estimated in the €450–900M range and EBITDA in the €50–100M bracket (FY 2015). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.